logo

For the Inventor, By the Inventor

Tsu, Japan

Yoshihiro Miyahara

This inventor holds 8 USPTO granted patents and 1 EPO patent. Top assignees: Mie University, Takara Bio Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshihiro Miyahara. Retrieved from https://idiyas.com/inventor/yoshihiro-miyahara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 37.5

 

Average Co-Inventor Count = 4.9

ph-index = 2

Forward Citations = 7(Granted Patents)


Location History:

  • Houston, TX (US) (2011 - 2015)
  • Tsu, JP (2012 - 2022)

Company Filing History:

goldMedal8 out of 85 
 
Mie University
 patents
silverMedal5 out of 150 
 
Takara Bio Inc.
 patents
where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 12637658 - METHOD FOR GENE TRANSFER INTO GAMMA-DELTA TYPE T CELL (2026-05-26),
2. 12479901 - T-CELL RECEPTOR (2025-11-25),
3. 11497768 - Antigen-binding protein that recognizes MAGE-A4-derived peptide (2022-11-15),
4. 9243227 - Cytotoxic T lymphocyte (2016-01-26),
5. 8951510 - T-cell receptor and nucleic acid encoding the receptor (2015-02-10),
6. 8383401 - T-cell receptor and nucleic acid encoding the receptor (2013-02-26),
7. 8168191 - Cytotoxic T lymphocyte (2012-05-01),
8. 8003770 - T-cell receptor and nucleic acid encoding the receptor (2011-08-23),

Title: Innovations by Yoshihiro Miyahara

Introduction

Yoshihiro Miyahara is a notable inventor based in Tsu, Japan. He has made significant contributions to the field of cancer therapy through his innovative patents. With a total of six patents to his name, he has focused on developing advanced techniques for treating cancer.

Latest Patents

One of his latest patents involves an antigen-binding protein that recognizes the MAGE-A4-derived peptide. This innovation is particularly relevant for CAR-T cell therapy, where the antibody recognizes the MAGE-A4-derived-peptide/HLA-A2 complex. The antibody includes specific amino acid sequences, which enhance its effectiveness in targeting cancer cells. Another significant patent relates to cytotoxic T lymphocytes, which have the ability to induce T lymphocytes that recognize specific antigens. This technique holds promise for improving cancer treatment outcomes.

Career Highlights

Yoshihiro Miyahara has worked with esteemed institutions such as Mie University and Takara Bio Inc. His work has been instrumental in advancing cancer therapies and improving patient outcomes. His dedication to research and innovation has established him as a key figure in his field.

Collaborations

He has collaborated with notable colleagues, including Hiroshi Shiku and Atsunori Hiasa. These partnerships have contributed to the development of groundbreaking technologies in cancer treatment.

Conclusion

Yoshihiro Miyahara's contributions to cancer therapy through his patents and collaborations highlight his importance as an inventor. His work continues to influence the field and offers hope for improved cancer treatments in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…